MaxCyte Stock (NASDAQ:MXCT)

MaxCyte, Inc. is a global life sciences enterprise focused on the innovation, advancement, and commercialization of next-generation cell therapies. The company offers a suite of advanced electroporation systems, including the ExPERT ATx, a static device for small to medium-scale cell transfection; the ExPERT STx, which uses flow electroporation to support protein production, drug development, and the expression of therapeutic targets for cell-based assays; the ExPERT GTx, another flow electroporation solution designed for large-scale transfection in therapeutic applications; and the ExPERT VLx, catering to very high-volume cell engineering needs. Additionally, MaxCyte provides disposable processing assemblies (PAs) crucial for cell processing and electroporation, alongside essential accessories such as electroporation buffer solutions and specialized software protocols. The company, established in 1998, operates from its headquarters in Rockville, Maryland.